Literature DB >> 23257520

Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease.

Shunsei Hirohata1, Hirotoshi Kikuchi.   

Abstract

OBJECTIVE: Neurological manifestations of Behçet's disease (NB) are serious complications. However, their pathogenesis remains unclear. The current study examined the levels of proinflammatory cytokines, including IL-1β, IL-6, IL-8 and TNF-α, in cerebrospinal fluid (CSF).
METHODS: CSF cytokines were measured using an enzyme-linked immunosorbent assay. CSF was obtained from 17 patients with acute NB, 19 patients with chronic progressive NB and 20 patients with non-inflammatory neurological diseases, including cerebrovascular disease, cervical spondylosis and degenerative diseases.
RESULTS: CSF total cell counts and polymorph nuclear leukocyte counts were significantly lower in the patients with chronic progressive NB than in those with acute NB. The CSF levels of IL-6 and IL-8 were markedly elevated in the NB patients compared with those measured in the control patients. There were no significant differences in the CSF levels of IL-6 and IL-8 between the patients with acute NB and those with chronic progressive NB. In contrast, there were no significant differences in the CSF levels of IL-1β and TNF-α among the control, acute NB and chronic progressive NB patients. Consistently, the CSF levels of IL-6 and IL-8 were significantly decreased following successful treatment in both acute NB and chronic progressive NB patients, whereas the CSF levels of IL-1β and TNF-α were not changed significantly. Of note, the CSF levels of IL-6 were significantly correlated with the CSF levels of IL-8 in the patients with acute NB (r =0.7647, p =0.0003) but not in the patients with chronic progressive NB (r =0.1343, p =0.5835).
CONCLUSION: These results indicate that CSF IL-6 and IL-8 play important roles in the pathogenesis of NB. However, the data also suggest that the mechanisms underlying the elevation of CSF IL-6 and IL-8 might be different in patients with acute NB and those with chronic progressive NB.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257520     DOI: 10.2169/internalmedicine.51.8583

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

Review 1.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

2.  Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.

Authors:  Jinjing Liu; Dong Yan; Zhimian Wang; Yunjiao Yang; Shangzhu Zhang; Di Wu; Lingyi Peng; Zhichun Liu; Wenjie Zheng
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-11-16       Impact factor: 5.346

Review 3.  New approaches to divorce with children: A problem of public health.

Authors:  Vittorio Carlo Vezzetti
Journal:  Health Psychol Open       Date:  2016-11-15

4.  Differential Gene Expression Patterns in Blood and Cerebrospinal Fluid of Multiple Sclerosis and Neuro-Behçet Disease.

Authors:  Olfa Maghrebi; Mariem Hanachi; Khadija Bahrini; Mariem Kchaou; Cyrine Jeridi; Samir Belal; Samia Ben Sassi; Mohamed-Ridha Barbouche; Oussama Souiai; Meriam Belghith
Journal:  Front Genet       Date:  2021-02-26       Impact factor: 4.599

5.  Increased T-bet/GATA-3 and ROR-γt /Foxp3 Ratios in Cerebrospinal Fluid as Potential Criteria for Definite Neuro-Behçet's Disease.

Authors:  Meriam Belghith; Olfa Maghrebi; Aroua Cherif; Khadija Bahrini; Zakaria Saied; Samir Belal; Samia Ben Sassi; Mohamed-Ridha Barbouche; Mariem Kchaou
Journal:  J Clin Med       Date:  2022-07-29       Impact factor: 4.964

6.  Analysis of a Functional IL-6 Gene Polymorphism in HLAB27 Associated and Intermediate Uveitis Gives New Insight in Disease Pathogenesis and Commonality with Other Autoimmune Diseases.

Authors:  Lindner Ewald; Langner-Wegscheider Beate; Sarny Stephanie; Renner Wilfried; El-Shabrawi Yosuf
Journal:  J Immunol Res       Date:  2015-11-10       Impact factor: 4.818

7.  Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.

Authors:  Toshifumi Hibi; Shunsei Hirohata; Hirotoshi Kikuchi; Ukihide Tateishi; Noriko Sato; Kunihiko Ozaki; Kazuoki Kondo; Yoshiaki Ishigatsubo
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

8.  Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: meta-analysis.

Authors:  Mizuho Ishido; Nobuyuki Horita; Masaki Takeuchi; Etsuko Shibuya; Takahiro Yamane; Tatsukata Kawagoe; Takehito Ishido; Kaoru Minegishi; Ryusuke Yoshimi; Yohei Kirino; Shunsei Hirohata; Yoshiaki Ishigatsubo; Mitsuhiro Takeno; Takeshi Kaneko; Nobuhisa Mizuki
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

9.  T-cell Lymphoma Presenting Neutrophilic Inflammation in the Cerebrospinal Fluid.

Authors:  Takaaki Nakamura; Yoshiki Takai; Kimihiko Kaneko; Hiroshi Kuroda; Tatsuro Misu; Kiyotaka Asanuma; Ryoko Saito; Masashi Aoki
Journal:  Intern Med       Date:  2019-10-07       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.